Media Coverage DAA-1 Study

The article highlighted that the “made in Singapore” anti-diabetic drug, DAA-I, has successfully completed its Stage I clinical trial and is the result of 20 years of extensive  research and was a joint collaboration between NUS Yong Loo Lin School of Medicine, Singapore Clinical Research Institute and the National University Health System. The article also covered key points on the drug’s mechanism and its benefits over current treatment for diabetes, as well as future plans for the development of the drug.

« Back